Skip to main content

Drug Interactions between betibeglogene autotemcel and Siklos

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

hydroxyurea betibeglogene autotemcel

Applies to: Siklos (hydroxyurea) and betibeglogene autotemcel

ADJUST DOSING INTERVAL: Hydroxyurea may affect the manufacturing and therapeutic efficacy of the autologous hematopoietic stem cell-based gene therapy, betibeglogene autotemcel. Haematopoietic stem cell (HSC) mobilization followed by apheresis to obtain CD34+ cells is required before betibeglogene autotemcel manufacturing, which involves genetic modification of human blood cells via a lentiviral vector. Hydroxyurea can inhibit DNA synthesis and alter red blood cells, and therefore, it may interfere with the manufacturing process. No data is currently available for this interaction.

MANAGEMENT: According to the manufacturer, hydroxyurea should be avoided for at least one month, or the expected duration of hydroxyurea elimination, prior to HSC mobilization and until all cycles of apheresis have been completed.

References (2)
  1. (2022) "Product Information. Hydroxyurea (hydroxyurea)." Par Pharmaceutical Inc
  2. (2022) "Product Information. Zynteglo (betibeglogene autotemcel)." bluebird bio

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer